Literature DB >> 25031704

A fiber-modified adenovirus co-expressing HSV-TK and Coli.NTR enhances antitumor activities in breast cancer cells.

Yang Zhan1, Bin Yu1, Zhen Wang2, Yu Zhang2, Hai-Hong Zhang1, Hao Wu2, Xiao Feng2, Ran-Shen Geng2, Wei Kong1, Xiang-Hui Yu1.   

Abstract

Breast cancers especially in late and metastatic stages remain refractory to treatment despite advances in surgical techniques and chemotherapy. Suicide gene therapy based on adenoviral technology will be promising strategies for such advanced diseases. We previously showed that co-expression of herpes simplex virus thymidine kinase (HSV-TK) and Escherichia coli nitroreductase (Coli.NTR) by an hTERT-driven adenovirus vector resulted in additive anti-tumor effects in breast cancer cells in vitro and in vivo. As many tumor tissue and cancer cells express low level of coxsackie-adenovirus receptor (CAR), which is the functional receptor for the fiber protein of human adenovirus serotype 5 (Ad5), novel Ad5 vectors containing genetically modifi ed fiber are attractive vehicles for achieving targeted gene transfer and improving suicide gene expression in these cancer cells. In the present study, we first built a simplified Ad5 vector platform for fiber modification and quick detection for gene transfer. Then a fiber-modified adenovirus vector containing an RGD motif in the HI loop of the fiber knob was constructed. After recombined with HSV-TK and Coli.NTR gene, this fiber-modified Ad5 vector (Ad-RGD-hT-TK/NTR) was compared with that of our previously constructed Ad5 vector (Ad-hT-TK/NTR) for its therapeutic effects in human breast cancer cell lines. The anti-tumor activity of Ad-RGD-hT-TK/NTR was significantly enhanced compared with Ad-hT-TK/NTR both in vitro and in vivo. This new vector platform provided a robust and simplified approach for capsid modification, and the fiber-modified Ad5 with double suicide genes under the control of hTERT promoter would be a useful gene therapy strategy for breast cancer.

Entities:  

Keywords:  Adenovirus; breast cancer; suicide gene

Mesh:

Substances:

Year:  2014        PMID: 25031704      PMCID: PMC4097267     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  36 in total

1.  Modulation of coxsackie-adenovirus receptor expression for increased adenoviral transgene expression.

Authors:  Akseli Hemminki; Anna Kanerva; Bin Liu; Minghui Wang; Ronald D Alvarez; Gene P Siegal; David T Curiel
Journal:  Cancer Res       Date:  2003-02-15       Impact factor: 12.701

2.  Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors.

Authors:  A H Djeha; T A Thomson; H Leung; P F Searle; L S Young; D J Kerr; P A Harris; A Mountain; C J Wrighton
Journal:  Mol Ther       Date:  2001-02       Impact factor: 11.454

3.  Structural basis for variation in adenovirus affinity for the cellular coxsackievirus and adenovirus receptor.

Authors:  Jason Howitt; Maria C Bewley; Vito Graziano; John M Flanagan; Paul Freimuth
Journal:  J Biol Chem       Date:  2003-04-25       Impact factor: 5.157

4.  Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma.

Authors:  Roberto Ria; Angelo Vacca; Domenico Ribatti; Francesco Di Raimondo; Francesca Merchionne; Franco Dammacco
Journal:  Haematologica       Date:  2002-08       Impact factor: 9.941

Review 5.  Use of suicide genes for cancer gene therapy: study of the different approaches.

Authors:  G Vassaux; P Martin-Duque
Journal:  Expert Opin Biol Ther       Date:  2004-04       Impact factor: 4.388

6.  Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer.

Authors:  Markus D Sachs; Katherine A Rauen; Meera Ramamurthy; Jennifer L Dodson; Angelo M De Marzo; Mathew J Putzi; Mark P Schoenberg; Ronald Rodriguez
Journal:  Urology       Date:  2002-09       Impact factor: 2.649

7.  Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes.

Authors:  Guenther Koehne; Mikhail Doubrovin; Ekaterina Doubrovina; Pat Zanzonico; Humilidad F Gallardo; Anna Ivanova; Julius Balatoni; Julie Teruya-Feldstein; Glenn Heller; Chad May; Vladimir Ponomarev; Shutian Ruan; Ronald Finn; Ronald G Blasberg; William Bornmann; Isabelle Riviere; Michel Sadelain; Richard J O'Reilly; Steven M Larson; Juri G Gelovani Tjuvajev
Journal:  Nat Biotechnol       Date:  2003-03-24       Impact factor: 54.908

8.  Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors.

Authors:  Yosef S Haviv; Jerry L Blackwell; Anna Kanerva; Peter Nagi; Victor Krasnykh; Igor Dmitriev; Minghui Wang; Seiji Naito; Xiaosheng Lei; Akseli Hemminki; Delicia Carey; David T Curiel
Journal:  Cancer Res       Date:  2002-08-01       Impact factor: 12.701

Review 9.  Prodrugs in genetic chemoradiotherapy.

Authors:  Adam V Patterson; Mark P Saunders; Olga Greco
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

10.  Noninvasive theranostic imaging of HSV1-sr39TK-NTR/GCV-CB1954 dual-prodrug therapy in metastatic lung lesions of MDA-MB-231 triple negative breast cancer in mice.

Authors:  Thillai V Sekar; Kira Foygel; Ohad Ilovich; Ramasamy Paulmurugan
Journal:  Theranostics       Date:  2014-02-15       Impact factor: 11.556

View more
  4 in total

1.  Mutation in fiber of adenovirus serotype 5 gene therapy vector decreases liver tropism.

Authors:  Zhen Wang; Baoming Wang; Junfang Lou; Jingyi Yan; Lei Gao; Ranshen Geng; Bin Yu
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 2.  Adenoviral vector-based strategies against infectious disease and cancer.

Authors:  Chao Zhang; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2016-04-22       Impact factor: 3.452

3.  A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.

Authors:  Zhen Wang; Bin Yu; Baoming Wang; Jingyi Yan; Xiao Feng; Zixuan Wang; Lizheng Wang; Haihong Zhang; Hui Wu; Jiaxin Wu; Wei Kong; Xianghui Yu
Journal:  Oncotarget       Date:  2016-07-26

Review 4.  Progresses towards safe and efficient gene therapy vectors.

Authors:  Sergiu Chira; Carlo S Jackson; Iulian Oprea; Ferhat Ozturk; Michael S Pepper; Iulia Diaconu; Cornelia Braicu; Lajos-Zsolt Raduly; George A Calin; Ioana Berindan-Neagoe
Journal:  Oncotarget       Date:  2015-10-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.